Acelyrin, Inc. is a late-stage clinical biopharmaceutical company focused on developing transformative therapies, particularly in the field of immunology. The company is actively investigating innovative treatments such as izokibep, an IL-17A inhibitor, and lonigutamab, an anti-IGF-1R therapy, targeting conditions like non-infectious uveitis and thyroid eye disease. Acelyrin's approach emphasizes the importance of addressing unmet patient needs through differentiated therapeutic strategies, with ongoing clinical trials aimed at demonstrating the efficacy of these treatments. The company is committed to accelerating the development and delivery of these medicines, reflecting a strong sense of urgency and a patient-first philosophy.

Acelyrin's pipeline includes several promising candidates, with izokibep currently in Phase 2b/3 trials for uveitis and Phase 3 trials for hidradenitis suppurativa and psoriatic arthritis. Lonigutamab is also progressing through Phase 2 and anticipated Phase 3 trials for thyroid eye disease. The company leverages a robust network of relationships across the pharmaceutical and biotech sectors to identify and acquire innovative therapeutic programs. By fostering collaboration and maintaining a focus on scientific excellence, Acelyrin aims to bring clinically meaningful therapies to market that can significantly improve patients' lives.

United States

ACELYRIN, INC.  (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising product candidates.

ACELYRIN is embedding a corporate culture of Courageous Caring™ -- placing patients first and embracing the concept that all of us are better than any one of us -- as we seek to addresses the most basic human needs: to live a productive life free from diseases. 

Endocrine System Diseases

Eye Diseases

Skin Diseases

Acelyrin

Eye disease

Thyroid Eye Disease

Lonigutamab

Hidradenitis suppurativa

<p class="font_8">Izokibep is a small therapeutic protein &nbsp;inhibitor of interleukin-17A (IL-17A) designed to overcome the &nbsp;limitations of monoclonal antibodies. With high potency and small &nbsp;molecular size – about one tenth the size of a traditional monoclonal &nbsp;antibody – izokibep can reach high drug exposure levels through a &nbsp;single, subcutaneous injection that monoclonal antibodies otherwise &nbsp;require IV administration to achieve. We have hypothesized that these &nbsp;characteristics could lead to clinically meaningful and differentiated &nbsp;impact in multiple diseases.</p>

Acelyrin

Company Details